Results: 3

1.
Figure 2

Figure 2. From: A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian Carcinoma.

Phenotypic properties of transformed ovarian cells and tumors that are wild-type or deficient for Brca1. A, ascites accumulation and carcinomatosis are apparent 4 to 10 weeks after i.p. injection of the Brca1 wild-type C2 cells (n = 10) and 10 to 14 weeks after i.p. injection of the Brca1-deficient BR5 cells (n = 16) into FVB mice. B, Brca1 wild-type and Brca1-deficient mouse tumors resemble human ovarian serous papillary carcinoma. H&E staining. C, Brca1 wild-type and Brca1-deficient mouse tumors are positive for the epithelial marker keratin 8 (K8).

Deyin Xing, et al. Cancer Res. ;66(18):8949-8953.
2.
Figure 3

Figure 3. From: A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian Carcinoma.

Sensitivity of Brca1 wild-type and Brca1-deficient cells to drugs with differential mechanisms of action. A, sensitivity of Brca1 wild-type (C1, C2, C3, T1, T2, and T3) and Brca1-deficient (BR2, BR5, BR6, TBR2, TBR5, and TBR6) cell lines to the microtubule poison paclitaxel and the DNA-damaging agent cisplatin. Results are ratio of the number of drug-treated cells to that of control cells. Points, mean of triplicate experiments; bars, SD. B, metaphase chromosome analysis of Brca1 wild-type (T1) and Brca1-deficient (TBR5) cell lines left untreated (inset) or exposed to 1 μmol/L cisplatin for 48 hours (main). Asterisks, triradial or quadriradial chromosomes.

Deyin Xing, et al. Cancer Res. ;66(18):8949-8953.
3.
Figure 1

Figure 1. From: A Mouse Model for the Molecular Characterization of Brca1-Associated Ovarian Carcinoma.

Characterization of genetically defined mouse ovarian cancer cell lines. A, detection of deleted p53 (exons 2–10), conditional Brca1, deleted Brca1 (exon 11), and tva alleles by PCR using DNA from mouse tails (2, 5, 6) and the corresponding transformed ovarian cell lines with deleted p53 and Brca1 tumor suppressor genes (BR2, BR5, and BR6). B, RT-PCR detection of p53, Brca1, Myc, and β-actin in MEFs and engineered mouse ovarian cancer cell lines C1 (p53−/−; Myc; K-ras), C2 (p53−/−; Myc; Akt), C3 (p53−/−; K-ras; Akt), and BR2, BR5, and BR6 (p53−/−; Brca1−/−; Myc). C, Western blot of whole-cell extracts from Brca1 wild-type (C22) and Brca1-deficient (BR2) cell lines with a mouse Brca1 antibody. Asterisk, nonspecific band. D, immunodetection of Rad51 nuclear foci formation after overnight exposure of Brca1 wild-type (C11) and Brca1-deficient (BR5) OSE cell lines to 1μg/mL MMC or vehicle.

Deyin Xing, et al. Cancer Res. ;66(18):8949-8953.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk